Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-MM-302 and Trastuzumab in Advanced HER2+ Cancer With Brain Metastases
NCT02735798Phase 1Withdrawn
- Sponsor
- Alessa Therapeutics
- Start
- Apr 2016
- Primary completion
- Jun 2017
- Modality
- Antibody Fragments, Targeted Liposomes, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label, single-arm trial of gancotamab in solid tumor and brain metastases, sponsored by Alessa Therapeutics. Primary endpoint: MM-302 drug penetration into the brain at 3 hours. Planned start Apr 2016; status: withdrawn.
02
Drugs
gancotamab
03
Conditions
solid tumorbrain metastases
Beyond the preview
Go deeper on NCT02735798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735798.